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Type 2 diabetes (T2D) is an important risk factor to suffer dementia, being Alzheimer's 
disease (AD) the most common form. Both, AD and T2D, are closely related to ageing 
and with a growing elderly population it might be of relevance to explore new 
therapeutic approaches that may slow or prevent central complications associated with 
metabolic disorders. Therefore, we propose the use of the antidiabetic polypill (PP), a 
pharmacological cocktail, commonly used by T2D patients that includes metformin, 
aspirin, simvastatin and an angiotensin-converting enzyme inhibitor. In order to test the 
effects of PP at the central level, we have long-term treated a new mixed model of AD-
T2D, the APP/PS1xdb/db mouse. We have analyzed AD pathological features and the 
underlying specific characteristics that relate AD and T2D. As expected, metabolic 
alterations were ameliorated after PP-treatment in diabetic mice, supporting a role for 
PP in maintaining pancreatic activity. At central level, PP reduced T2D-associated brain 
atrophy, showing both neuronal and synaptic preservation. Tau and amyloid pathology 
were also reduced after PP treatment. Furthermore, we observed a reduction of 
spontaneous central bleeding and inflammation after PP treatment in diabetic mice. As  
consequence, learning and memory processes were improved after PP treatment in AD, 
T2D and AD-T2D mice. Our data provide the basis to further analyze the role of PP, as 
an alternative or adjuvant, to slow down or delay the central complications associated 
with T2D and AD. 




The increase in life expectancy is contributing to a significant increase in the 
pathologies associated with aging. Among these, Alzheimer's disease (AD) and vascular 
dementia (VaD) are the most prevalent forms of dementia [1]. The main 
neuropathological features of AD are senile plaques (SP), neurofibrillary tangles, and 
neuronal and synaptic loss, with the latter correlating most strongly with the severity of 
the disease [2]. On the other hand, VaD is a heterogeneous disease that includes 
multiple microinfarcts, ischemic disease and microvascular damage [3]. AD pathology 
regularly coexists with vascular injury, making the borderlines between AD and VaD 
blurred in many cases [3]. The underlying causes of dementia are not completely 
understood and while aging remains the main risk factor to suffer AD, metabolic related 
alterations also increase the risk to develop AD. Following this idea, hyperinsulinemia 
and type 2 diabetes (T2D) are the metabolic factors that show a stronger association 
with dementia [4-5]. In recent years, multiple studies have reported the impact of insulin 
dysfunction and diabetes on tau pathology [6-7]. In addition, central nervous system 
insulin receptors are highly expressed in regions relevant for cognition, such as the 
cortex and hippocampus. This is consistent with evidence showing that insulin 
influences memory [3]. It has also been suggested that Aβ clearance, along interstitial 
fluid drainage pathways, can be reduced when there is central vascular damage [8] and 
T2D is also closely related with vascular dysfunction [9]. Insulin may regulate Aβ 
levels by modulation of β and γ secretases [10] and Aβ oligomers may also interfere 
with insulin signalling in hippocampal neurons [11]. It is therefore feasible that 
metabolic alterations may also underlie the crosstalk between T2D and AD [12].  
At present, there are no effective treatments for AD and current pharmacological 
approaches are limited to anti-cholinesterase drugs or memantin. For this reason, new 
treatments that may ameliorate the symptoms of AD are urgently needed. The anti-T2D 
polypill (PP) might be a useful tool to reduce the number of deaths and serious 
complications caused by diabetes [13]. PP contains several drugs commonly used to 
treat T2D, including metformin, aspirin, a generic statin, and a angiotensin-converting 
enzyme inhibitor (ACEi) [13]. Moreover, a commercially available version of a PP, that 
combines aspirin, a statin and an ACEi, is already available in Europe (Trinomia®). The 
pathological basis for the relationship between T2D and AD-VaD may also support PP, 
as a therapy that may treat, prevent or delay central pathology in dementias and T2D. 
Previous studies have focused on the isolated components of the PP to treat dementia, 
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however to our knowledge the so-called PP has not been assessed at central level. In our 
hands, long-term PP treatment improved metabolic alterations observed in diabetic mice 
(both db/db and APP/PS1xdb/db). At central level, we detected a significant 
improvement in amyloid pathology and reduced tau hyperphosphorylation, as well as 
brain integrity preservation. Furthermore, spontaneous central bleeding and 
neuroinflammation were reduced after PP-treatment. These effects were accompanied 
by a significant improvement of learning and memory deficits after long-term treatment, 
supporting a role for PP in the management of central pathology associated with AD 
and T2D. 
 
Material and Methods 
1. Animals and treatments 
AD-T2D mice were produced by cross-breeding APPswe/PS1dE9 with db/db mice [14-
15]. Both females and males were included and a similar number of males and females 
were used in each experiment. The animals were randomly divided into groups and 
received PP included in the diet from 4 to 26 weeks of age. Dosage of individual PP 
components were selected from previous studies using individual drugs: metformin 
(200 mg/Kg/day)[16], simvastatin (40 mg/kg/day) [17], aspirin (5 mg/kg/day) [18], 
perindopril (0.5 mg/kg/day) [19] and included in food pellets (SAFE A04, France). 
Dosing was adjusted to daily food intake (~6 g for diabetic mice and ~3,6 for non 
diabetic mice), in line with previous studies [20]. Briefly, powder diet was thoroughly 
mixed with the powered drugs and distilled water (50ml of distilled water per 100g of 
diet), compacted in cubes and dried at 37ºC in a stove (Raypa Incuterm, Spain) 
overnight. New food batches were prepared every 48h. All experimental procedures 
were approved by the Animal Care and Use Committee of the University of Cadiz, in 
accordance with the Guidelines for Care and Use of experimental animals (European 
Commission Directive 2010/63/UE and Spanish Royal Decree 53/2013). 
 
2. Plasma determinations 
Body weight, postprandial blood glucose and plasma insulin levels were determined 
before treatment and every 4 weeks until sacrifice at 26 weeks. Total cholesterol, high-
density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides were 
measured in plasma by enzymatic colorimetric method with autoanalyzer Cobas c 8000 
at 26 weeks of age (Roche Diagnostic®) following manufacturer’s indications. ACE 
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activity was measured by Infinity ACE assay (Thermo Fisher, USA) following 
manufacturer´s indications. All determinations were perfomed in 5-15 mice (Control 
n=11, Control-PP N=15, APP/PS n=12, APP/PS1-PP n=12, db/db n=10, db/db-PP=10, 
APP/PSxdb/db n=5, APP/PS1xdb/db-PP n=5). 
 
3. Morris water maze (MWM) 
Spatial cognition was analyzed as previously described [15]. The maze consisted of a 
round tank of water (0.95 m in diameter) with four equal virtual quadrants indicated 
with geometric cues mounted on the walls. The escape platform was 2-3 cm below the 
surface and camouflaged with calcium carbonate. A camera was mounted above the 
maze and attached to a computer and software. Water temperature was 21±1ºC. Testing 
was conducted in two phases: acquisition and retention. The acquisition consisted of 4 
trials/day for 4 consecutive days with the platform submerged. During this phase, the 
platform was located in the quadrant 2. The time limit was 60 s/trial with an intertrial 
interval of 10 min. If the animal did not find the platform, it was placed on it for 10 s. 
The retention phase started a day after acquisition phase was completed, and consisted 
in a single trial with the platform removed. Time required to locate the platform in the 
acquisition phase, percentage of time spent in quadrant 2 during the retention phase and 
swim speed were analyzed using Smart software (Panlab, Spain). MWM studies include 
7-16 mice pre group (Control n=12, Control-PP N=16, APP/PS n=15, APP/PS1-PP 
n=12, db/db n=10, db/db-PP=8, APP/PSxdb/db n=8, APP/PS1xdb/db-PP n=7). 
 
4. Actimetry and novel object discrimination (NOD) task  
Episodic memory was assessed with the NOD test as previously described [21] with minor 
modifications. We assessed spontaneous locomotor activity prior the commencement of the 
NOD test. Briefly, on day 1, mice were allowed to explore a transparent rectangular box (22 cm 
long x 44 cm width x 40 cm high) for 30 minutes. Animals were recorded, and distance 
travelled and speed were measured by Smart software (Panlab, Spain). NOD test commenced 
on day 2 and animals were exposed to two objects, for habituation purposes, not used again 
during the object exploration task. On day 3, each mouse received two sample trials and a test 
trial. On the first sample trial, mice were placed into the centre of the box containing 4 copies of 
a novel object (blue balls) arranged in a triangle-shaped spatial configuration and allowed to 
explore them for 5 min. After a delay of 30 min, the mice received a second sample trial with 4 
novel objects (red cones), arranged in a quadratic-shaped spatial configuration, for 5 min. After 
a delay of 30 min, the mice received a test trial with 2 copies of the object from sample trial 2 
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(“recent” objects) placed at the same position, and two copies of the object from sample trial 1 
(“familiar” objects) placed one of them at the same position (“old non displaced” object) and the 
another in a new position (“familiar displaced” object). Integrated episodic memory for "what", 
"where" and "when" was analyzed as previously described [21]: "what" was defined as the 
difference in time exploring familiar and recent objects, "where" was defined as the difference 
in time exploring displaced and non displaced objects and "when" was defined as the difference 
between time exploring familiar non displaced and recent non displaced objects. Actimetry and 
NOD test studies included 7-16 mice per group (Control n=12, Control-PP N=16, 
APP/PS n=15, APP/PS1-PP n=12, db/db n=10, db/db-PP=8, APP/PSxdb/db n=8, 
APP/PS1xdb/db-PP n=7). 
 
5. Cresyl violet staining 
Brain sections were selected 1 mm apart (from 1.5 to -3.5 mm from Bregma). Sections 
were mounted and dehydrated in 70% ethanol for 15 minutes before incubation in cresyl 
violet as previously described [22]. Images were acquired using an optical Olympus 
Bx60 microscope with an attached Olympus DP71 camera and Cell F software 
(Olympus, Hamburg, Germany). Cortex and hippocampus cross-sectional areas were 
measured using Image J software in 5-7 mice per group (Control n=6, Control-PP N=7, 
APP/PS n=7, APP/PS1-PP n=5, db/db n=7, db/db-PP=7, APP/PSxdb/db n=6, 
APP/PS1xdb/db-PP n=7). 
 
6. Prussian blue staining 
Presence of spontaneous haemorrhages was assessed postmortem by Prussian blue iron 
staining and neutral red counterstaining. Consecutive sections to those used for cresyl 
violet staining were processed as previously described [22], and images were analyzed 
using Image J software to quantify haemorrhage burden in the cortex and hippocampus 
of all groups studied (Control n=7, Control-PP N=5, APP/PS n=5, APP/PS1-PP n=4, 
db/db n=6, db/db-PP=4, APP/PSxdb/db n=5, APP/PS1xdb/db-PP n=5). 
 
7. Total-tau and phospho-tau levels 
Total tau and tau phosphorylation levels were measured in cortical and hippocampal 
samples. Tissue was homogenized in lysis buffer (Cell Signaling, USA) and 
supplemented with a protease and phosphatase inhibitor cocktail (Sigma, USA). The 
homogenates were sonicated and centrifuged at 4 ºC for 5 min at 15.000 g. Supernatants 
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were collected and protein concentration determined by Bradford protein assay (Biorad, 
Germany). Proteins were separated on 10% acrylamide-bisacrylamide gels, followed by 
electrophoretic transfer to PVDF membranes (Schleicher & Schuell, Keene, NH).  
Membranes were then immersed in blocking buffer (Invitrogen, USA) for 1 h and 
incubated overnight at 4ºC with primary antibodies for anti-phospho-tau antibody 
(1:1000) (clon AT8, Fisher Scientific, Waltham, Ma). Membranes were washed and 
then incubated with chemiluminescent inmunodetection system for mouse and rabbit 
primary antibodies respectively (Invitrogen, Carlsbad, USA). Membranes were washed 
and signal was detected using Novex AP Chemiluminescent Substrate (Invitrogen, 
USA) and Kodak Biomax Light Film (Sigma, USA). After stripping, membranes were 
incubated with anti-total tau (1:1000) (DAKO, Glostrup, Denmark). Immunoblots were 
semi-quantified by measuring the optical density (OD) of each protein band on scanned 
film using the ImageJ software. Each band was normalized to β-actin (1:2.500.000; 
Sigma, USA) optical density, and phospho tau/ total tau ratio was represented from 6-9 
mice per group (Control n=8, Control-PP N=6, APP/PS n=7, APP/PS1-PP n=7, db/db 
n=9, db/db-PP=7, APP/PSxdb/db n=6, APP/PS1xdb/db-PP n=6). 
  
8. Aβ40 and Aβ42 levels 
Soluble and insoluble Aβ40 and Aβ42 were quantified in frozen cortex and 
hippocampus using colorimetric ELISA kits (Wako, Japan) as previously described with 
minor modifications [23]. Tissue (5-10 mg) was homogenized in 50μl of lysis buffer 
with inhibitor cocktail (Thermo Scientific Pierce, Spain) and centrifuged 14.500 rpm for 
12 min at 4°C. Supernatants were diluted 1:300 for soluble Aβ40 and 42 levels. The 
resultant pellet was then extracted with 50μl of 70% formic acid and then centrifuged. 
Insoluble fraction was neutralized with 1M Tris (pH 11) and diluted 1:10. Standard 
curves were made using human Aβ40 and Aβ42 standards provided in the kit. 
Absorbance was measured spectrophotometrically at 450 nm (MQX200R2, Biotek 
instruments, Burlington VT, USA) and data were expressed as pmol/g tissue (Control 
n=6, Control-PP N=6, APP/PS n=10, APP/PS1-PP n=10, db/db n=6, db/db-PP=6, 
APP/PSxdb/db n=14, APP/PS1xdb/db-PP n=14). 
 
 
10. Senile plaques and microglia immunostaining  
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After pretreatment in 70% formic acid, sections were incubated in anti-Iba1 (Wako, 
Osaka, Japan) (1:1.000) and anti Aβ (4G8, Covance, Greenfield, IN, USA) (1:2000) 
antibodies overnight at 4º C in 0.5% NGS. Secondary antibodies Alexa Fluor 594 and 
Alexa Fluor 488 (Molecular Probes, OR, USA) (1:1.000) were used. Sections were 
mounted and photographed using a fluorescent microscope (Laser Microdissection 
System CellCut Version 4.3, Molecular Machines & Industries AG, Switzerland). SP 
burden was analyzed in the cortex and hippocampus. Microglia burden was also 
quantified using Image J software. Regions of interest were marked around SP (up to 
50µm from the plaque border) to quantify microglia burden in the proximity of amyloid 
deposits. Microglia burden was also measured in random SP-free areas from APP/PS1 
and APP/PS1xdb/db mice, and in animals without plaques (Control and db/db mice), as 
previously described [14, 24] (Control n=5, Control-PP n=5, APP/PS n=4, APP/PS1-PP 
n=4, db/db n=5, db/db-PP=4, APP/PSxdb/db n=4, APP/PS1xdb/db-PP n=5). 
. 
 
11. Neuron immunostaining senile plaques staining 
Sections were blocked in 3% BSA with 0.1% Tritón-X in PBS for 1h, followed by anti-
NeuN antibody (Chemicon) incubation (1:200) overnight at 4º C, in 0.5% BSA. 
Conjugated goat anti-mouse Alexa 594 antibody was used as secondary antibody. 
Sections were washed and stained with DAPI 1mg/ml (Sigma, St. Louis, MO, USA) 
(1:3000) and thioflavin S staining was used to label SP. Sections were mounted and 
photographed using a Laser Olympus U-RFL-T fluorescent microscope (Olympus, 
Japan) and MMIcellTools software. Aβ burden was analyzed in the cortex and 
hippocampus. The percentage of NeuN-positive cells (normalized by total cells stained 
with DAPI) was quantified in the cortex and hippocampus from 3 mice per group, close 
(up to 50µm from the plaque border) and far from plaques (>50µm from SP). 
 
12. Array tomography  
Synaptic density was assessed by array tomography as previously described [25] with 
minor modifications. Cortical samples were fixed in 4 % PFA for 4 h, dehydrated and 
immersed into LR White resin (Electron Microscopy Sciences) and polymerized 
overnight at 53 °C. Sections were rehydrated for 5 min with 50 mM glycine in TBS and 
blocked for 5 min in 0.05 % Tween and 0.1 % BSA. Ribbons were incubated on “day1” 
with antibodies against synaptophysin (Abcam, USA) and PSD95 (Cell signaling, USA) 
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(1:100) overnight at 4ºC. Secondary antibodies Alexa Fluor 594 and 488 (Invitrogen, 
USA) were incubated (1:50) in blocking buffer for 30 min. Sections were 
counterstained with 0.01 mg/mL DAPI for 5 min. Images were obtained along the 
ribbon using a Zeiss Axio Imager Z2 epifluorescent microscope with a CoolSnap digital 
camera and AxioImager software with array tomography macros (Carl Zeiss, Ltd, 
Cambridge UK). High-resolution images were obtained with a 63×1.4 NA Plan 
Apochromat objective. Coverslips were washed twice in TBS and stripped with 
stripping buffer (0.2 M NaOH and 0.02 % SDS in TBS). Coverslips were washed with 
TBS and quickly washed 3 times in H2Odd. The staining protocol was then repeated 
(“day2”) with antibodies against synapthophysin (1:100) and AW7 (1:1.000) for 
plaques (Dr. Dominic Walsh, USA). Images from “day1” and “day2” were aligned, and 
regions of interest (crops) chosen in the neuropil. The combined role of the SP halo 
effect and metabolic alterations on the synaptic density was assessed in both SP free 
areas (distance from SP >50 μm) and close to plaque borders (distance from SP <50 
μm). Synaptic puncta and volumes were generated using MATLAB scripts from Dr. 
Spires-Jones laboratory in 4-5 mice per group (Control n=5, Control-PP N=5, APP/PS 
n=5, APP/PS1-PP n=5, db/db n=4, db/db-PP=5, APP/PSxdb/db n=5, APP/PS1xdb/db-
PP n=5).  
 
13. Statistical analysis 
Student t test for independent samples, one-way ANOVA for independent samples 
followed by Tukey b or Tamhane tests, or 2 way ANOVA were used to compare the 
groups under study. SPSS v.20 software was used for all statistical analysis. 
 
Results 
1. PP treatment improves metabolic parameters in db/db and APP/PS1xdb/db mice  
As previously described [14], body weight was significantly increased in db/db and 
APP/PS1xdb/db mice up to 26 weeks of age (Figure 1A). We detected a significant 
weekXgroup effect when body weight was compared between groups by two-way 
ANOVA [F(35,373)=10.98, **p<0.01]. Further differences on weekly intervals were 
detected by one way ANOVA for independent samples followed by Tukey b or 
Tamhane tests as required (week 4 [F(7,66)=9.20, ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP], week 8 [F(7,72)=46.93, ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP], week 12 [F(7,79)=32.09, ‡‡p<0.01 vs. Control, Control-PP, 
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APP/PS1 and APP/PS1-PP], week 16 [F(7,79)=35.21, ††p<0.01 vs. Control, Control-PP, 
APP/PS1, APP/PS1-PP, db/db and APP/PS1xdb/db; ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP], week 20 [F(7,77)=33.17 ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP; ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, 
db/db and APP/PS1xdb/db], week 24 [F(7,78)=25.33 ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP; ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, 
db/db and APP/PS1xdb/db]) (Figure 1A).  
We detected a significant weekXgroup effect when we analyzed postprandial glucose 
levels [F(35,374)=7.97, **p<0.01]. Further analysis was performed by one-way ANOVA 
followed by Tukey b or Tamnhane tests as required. PP treatment reduced glucose 
levels in diabetic mice after 4 weeks of treatment (8 weeks of age), and this effect was 
more pronounced in APP/PS1xdb/db after 12 weeks under PP-treatment (week 4 
[F(7,72)=3.085, p=0.07], week 8 [F(7,71)=52.67, ††p<0.01 vs. Control, Control-PP, 
APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP; ‡‡p<0.01 vs. Control, 
Control-PP, APP/PS1 and APP/PS1-PP], week 12 [F(7,79)=34.49, ††p<0.01 vs. Control, 
Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP; ‡‡p<0.01 vs. 
Control, Control-PP, APP/PS1 and APP/PS1-PP], week 16 [F(7,78)=60.43, **p<0.01 vs. 
rest of the groups; ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP 
and APP/PS1xdb/db-PP; ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-
PP], week 20 [F(7,76)=39.54, **p<0.01 vs. rest of the groups; ††p<0.01 vs. Control, 
Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP; ‡‡p<0.01 vs. 
Control, Control-PP, APP/PS1 and APP/PS1-PP], week 24 [F(7,77)=49.04, **p<0.01 vs. 
rest of the groups; ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP 
and APP/PS1xdb/db-PP; ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP] 
(Figure 1B). 
We also observed a significant weekXgroup effect when insulin levels were compared 
[F(35,370)=1,65, **p<0.01]. Insulin levels were significantly increased in all diabetic mice 
before the commencement of treatment at 4 weeks of age (week 4 [F(7,72)=7.74, ‡‡ 
p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP]). Reduction of insulin 
levels were more pronounced in APP/PS1xdb/db mice, and PP treatment rescued insulin 
levels in both db/db-PP and APP/PS1xdb/db-PP mice after 4 weeks of treatment (Figure 
1C) (week 8 [F(7,69)=19.27, ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-
PP; ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db and 
APP/PS1xdb/db], week 12 [F(7,78)=23.66, ††p<0.01 vs. Control, Control-PP, APP/PS1, 
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APP/PS1-PP, db/db and APP/PS1xdb/db; ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 
and APP/PS1-PP], week 16 [F(7,73)=22.16, ††p<0.01 vs. Control, Control-PP, APP/PS1, 
APP/PS1-PP, db/db and APP/PS1xdb/db; ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 
and APP/PS1-PP], week 20 [F(7,77)=14.12, ††p<0.01 vs. Control, Control-PP, APP/PS1, 
db/db and APP/PS1-PP], week 24 [F(7,79)=8.9, ††p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP]) (Figure 1C). Altogether, metabolic assessment revealed an 
early exhaustion of beta-pancreatic cells in db/db and APP/PS1xdb/db mice, leading to 
reduced insulin production and higher glucose levels, with this effect partially restored 
in treated mice. 
Lipid profile was significantly affected in diabetic mice and total cholesterol levels were 
increased in db/db mice [F(7,70)=3.64, ††p=0.002 vs. Control, Control-PP, APP/PS1 and 
APP/PS1-PP], while HDL levels were significantly reduced in db/db and 
APP/PS1xdb/db mice. PP treatment reduced these effects, although differences did not 
reach statistical significance [F(7,72)=1.88, p=0.084]. PP treatment also reduced LDL 
levels in db/db and APP/PS1xdb/db mice [F(7,71)=3.76, ††p=0.002 vs. Control, Control-
PP, APP/PS1 and APP/PS1-PP and ##p=0.002 vs. APP/PS1-PP]. PP treatment partially 
controlled triglyceride levels [F(7,67)=4.13, ††p=0.001 vs. Control, Control-PP, APP/PS1 
and APP/PS1-PP]. Plasmatic ACE activity was reduced after PP treatment reduced in 
db/db mice, reaching statistical significance in APP/PS1xd/db animals [F(7,71)=2.72, 
†p=0.015 vs. Control, Control, APP/PS1, db/db, APP/PS1xdb/db] (Table 1). 
 
2. PP treatment improves cognitive impairment in APP/PS1, db/db and APP/PS1xdb/db 
mice 
Episodic memory in the NOD was significantly impaired in APP/PS1 and db/db mice 
and a worsening effect was observed in APP/PS1xdb/db, as previously described [14-
15]. However, an overall improvement was observed after PP treatment (Figure 1D). A 
significant recovery was observed in APP/PS1xdbdb-PP treated mice when "what" 
paradigm was analyzed [F(7,226)=7,72, ††p<0.01 vs. Control, Control-PP, db/db-PP and 
APP/PS1xdb/db-PP, ##p<0.01 vs. Control and Control-PP, ‡‡p<0.01 vs. Control] 
(Figure 1D). For the "where" paradigm, we observed cognitive alterations in APP/PS1, 
db/db and APP/PS1xdb/db and PP treatment significantly improved diabetic mice 
performance [F(7,232)=13.05, ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-
PP, ##p<0.01 vs. Control and Control-PP]. Alterations observed in the "when" 
paradigm did not reach statistical significance [F(7,237)=1.73, p=0.101] (Figure 1D). 
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In the MWM, learning and memory abilities were impaired in APP/PS1 and db/db mice, 
showing a synergistic effect when both pathologies coexist in APP/PS1xdb/db mice, as 
previously described [14-15]. PP treatment partially rescued these alterations and this 
effect was more robust in APP/PS1xdbdb-PP mice (Figure 1E). We detected a 
significant groupXday effect by 2-way ANOVA [F(21,1196)=59.36, **p=0.01] during the 
acquisition phase in the MWM test and further differences were analyzed by one-way 
ANOVA for independent samples followed by Tukey b test. Reduced acquisition times 
were observed in APP/PS1 mice, db/db and APP/PS1xdb/db mice on PP-treatment and 
the effect of PP treatment was more pronounced in the APP/PS1xdb/db-PP group 
(Figure 1E). Day 1: [F(3,341)=5.50, ##p<0.01 vs. Control and Control-PP], day 2 
[F(7,304)=17.33, ##p<0.01 vs. Control and Control-PP, ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP, ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP 
and db/db-PP], day 3 [F(7,315)=26.05, ##p<0.01 vs. Control and Control-PP, ‡‡p<0.01 
vs. Control, Control-PP, APP/PS1 and APP/PS1-PP, ††p<0.01 vs. Control, Control-PP, 
APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP], day 4 [F(7,312)=267.60, 
♯♯p<0.01 vs. Control, Control-PP and APP/PS1-PP, ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP, **p<0.01 vs. rest of the groups] (Figure 1E). Spatial 
memory was assessed in the MWM test 24 h after completing the acquisition phase. We 
observed that db/db and APP/PS1 animals spent less time in quadrant 2, where the 
platform used to be located, this effect was more severe and statistically significant in 
APP/PS1xdb/db mice. However, PP-treatment partially rescued spatial memory, 
reaching statistical significance in APP/PS1xdb/db-PP mice [F(7,77)=3.42, ††p=0.003 vs. 
Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdbdb-PP] (Figure 
1F).   
Since db/db and APP/PS1xdb/db mice are overweight, motor activity was also evaluated 
and no differences were detected among groups (Control: 21481.05±2413.03cm; 
Control-PP: 19973.33±1002.48 cm; APP/PS1: 25125.66±1507.01 cm; APP/PS1-PP: 
23087.96±2865.09 cm; db/db: 197.92,30±2383.34 cm; db/db-PP: 18129.18±2086.45 
cm/s; APP/PS1xdb/db: 22445.00±3175.14 cm; APP/PS1xdb/db-PP: 19320.71±3259.73 
cm; [F(7,49)=1.06, p=0.401]). Swimming speed in the MWM test was significantly 
reduced in diabetic mice (both db/db and APP/PS1xdb/db) and this effect was 
maintained after PP treatment (Control: 23.71±0.41cm/s, Control-PP: 23.14±0.35 cm/s, 
APP/PS1: 23.44±0.55 cm/s, APP/PS1-PP: 23.44±0.51 cm/s, db/db: 12.99±0.91 cm/s, 
db/db-PP: 10.83±1.11 cm/s, APP/PS1xdb/db: 10.56±1.32 cm/s, APP/PS1xdb/db-PP: 
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10.02±1.22 cm/s), suggesting that observed cognitive improvement in treated mice was 
not due to motor activity improvement. 
 
3. PP treatment ameliorates brain atrophy and neuronal loss in diabetic mice 
Brain atrophy was observed in db/db mice and this effect was more severe in 
APP/PS1xb/db mice as previously described [15, 25]. Long-term PP treatment partially 
recovered this situation. These differences were readily detectable when we compared 
brain weight by one-way ANOVA followed by Tukey b test [F(7,79)=72.39, **p<0.01 vs. 
rest of the groups, ‡‡p<0.01 vs. Control, control-PP, APP/PS1, APP/PS1-PP and db/db-
PP, ††p<0.01. vs. Control, control-PP, APP/PS1 and APP/PS1-PP] (Figure 2A). Further 
cresyl violet staining revealed a significant reduction of cortical thickness, which was 
partially restored after PP treatment in db/db mice, this effect was statistically 
significant in APP/PS1xdb/db mice (Figure 2B and 2D). Differences were detected by 
one-way ANOVA followed by Tukey b test [F(7,297)=22.17, **p<0.01 vs. Control, 
Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP, ††p<0.01 vs. 
Control, Control-PP, APP/PS1, APP/PS1-PP]. While a similar profile was observed in 
the hippocampus, differences did not reach statistical significance [F(7,152)=0.113, 
p=0.997] (Figure 2C).  
When we analyzed NeuN-positive cells, we detected significant reductions in db/db and 
APP/PS1xdb/db mice, whilst PP treatment significantly improved the number of NeuN-
positive cells [F(7,2022)=5.65, ‡‡p<0.01 vs. Control, Control-PP, db/db-PP and 
APP/PS1xdb/db-PP,  ##p<0.01 vs. Control]. Similarly, reduced NeuN+/DAPI ratio in 
APP/PS1 and APP/PS1xdb/db mice was improved after PP treatment in the proximity of 
SP [F(7,2722)=4.20, ‡‡p=0.08 vs. APP/PS1xdb/db-PP] (Figure 2E and 2F). 
 
4. PP treatment rescues synaptic loss in db/db and APP/PS1xdb/db mice  
Array tomography on synaptophysin and PSD95 was performed to evaluate pre and 
postsynaptic densities respectively. Synaptic density was reduced in the proximity of SP 
in APP/PS1 and APP/PS1xdb/db mice as previously described [25], and no differences 
were observed after PP treatment among groups in areas close to SP for PSD95 
[F(3,396)=1.91, p=0.127] and synaptophysin [F(3,395)=0.838, p=0.474]) (Figure 3A, 3B and 
3C). When we analyzed SP free areas, we observed that even in the absence of amyloid 
pathology, db/db mice showed reduced pre- and post-synaptic densities, indicating that 
T2D may impair synapses. This synaptic loss was exacerbated in APP/PS1xdb/db mice, 
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probably due to a synergistic effect between amyloid pathology and T2D central 
pathology. PP-treatment completely reversed PSD95 loss in db/db and APP/PS1xdb/db 
mice [F(7,1065)=14.45, **p<0.01 vs. rest of the groups, ‡‡p<0.01 vs. Control, Control-PP, 
APP/PS1, APP/PS1-PP and APP/PS1xdb/db-PP] and a significant improvement was also 
observed in synaptophysin [F(7,1064)=8.23, ††p<0.01 vs. Control, Control-PP, APP/PS1, 
APP/PS1-PP, ‡‡p<0.01 vs. Control and Control-PP, ##p<0.01 vs. Control-PP] (Figure 
3A, 3B and 3C). 
 
5. PP treatment modifies amyloid pathology in APP/PS1 and APP/PS1xdb/db mice 
Diffuse and dense SP burdens were measured by 4G8 immunostaining and thioflavin S 
staining respectively. Cortical SP burden in APP/PS1xdb/db was reduced when 
compared with APP/PS1 mice, as previously described in this animal model [14-15]. PP 
treatment did not affect APP/PS1xdb/db SP burden, however it ameliorated SP 
deposition in APP/PS1 mice [F(3,106)=28.098, **p<0.01 vs. rest of the groups, ††p<0.01 
vs. APP/PS1xdb/db and APP/PS1xdb/db-PP] and a similar profile was observed when 
thioflavin S burden was analyzed [F(3,105)=8.98, ††p<0.01 vs. APP/PS1xdb/db and 
APP/PS1xdb/db-PP] (Figure 4A and 4B). The same trend was observed when the 
hippocampus was analyzed after 4G8 immunostaining [F(3,52)=9.47, ††p<0.01 vs. 
APP/PS1xdb/db and APP/PS1xdb/db-PP] and thioflavin S staining [F(3,45)=3.37, 
‡‡p=0.026 vs. APP/PS1xdb/db] (Figure 4A). We also analyzed cortical insoluble Aβ 
levels by ELISA: Aβ40 levels were significantly higher in APP/PS1 mice compared to 
APP/PS1xdb/db mice, and a significant reduction was observed after PP treatment 
[F(3,16)=4.4, *p=0.019 vs. rest of the groups], in accordance with our previous results on 
SP burden. A similar profile was observed when insoluble Aβ42 levels were measured, 
although differences did not reach statistical significance [F(3,16)=2.27, p<0.075] (Figure 
4C). We observed a similar pattern in the hippocampus for insoluble Aβ40 levels 
[F(3,18)=6.13, **p=0.005 vs. rest of the groups] and Aβ42 [F(3,16)=2.67, p=0.083] (Figure 
4C). 
Interestingly, when we analyzed cortical soluble Aβ40 levels, we detected a shift 
towards more toxic soluble species in APP/PS1xdb/db mice compared with APP/PS1 
animals, as previously described [14]; and PP-treatment reduced this effect [F(3,20)=3.41, 
‡p<0.035 vs. APP/PS1xdb/db-PP] (Figure 4C). A similar trend was observed when 
soluble Aβ42 levels were analyzed, although differences did not reach statistical 
significance [F(3,19)=2.61, p=0.081] (Figure 4C). Soluble Aβ levels showed a similar 
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trend in the hippocampus, although differences did not reach statistical significance 
(soluble Aβ40 [F(3,20)=2.01, p=0.144], soluble Aβ42 [F(3,19)=2.13, p=0.130]) (Figure 
4C).  
 
6. PP treatment reduces tau phosphorylation 
Tau phosphorylation was increased in db/db mice and further increased in 
APP/PS1xdb/db mice, as previously described [14-15]. PP-treatment limited tau 
hyperphosphorylation both in the cortex ([F(7,49)=2.67, †p=0.02 vs. Control, Control-PP, 
APP/PS1 and APP/PS1-PP]) (Figure 4D and 4E) and the hippocampus ([F(7,52)=5.84, 
##p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and 
APP/PS1xdbd/db-PP, ††p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP]) 
(Figure 4D).  
 
7. PP reduces central inflammation in diabetic mice 
In the cortex, when analyzed in the proximity of SP, microglia burden was higher in 
APP/PS1 mice compared with APP/PS1xdb/db mice, as previously described [15]. PP 
treatment significantly reduced microglia burden both in APP/PS1 and APP/PS1xdb/db 
mice [F(3,1064)=34.46, **p<0.05 vs. rest of the groups, ††p<0.01 vs. APP/PS1 and 
APP/PS1-PP, ‡‡p<0.01 vs. APP/PS1] (Figure 5A and 5B). In free SP areas we observed 
an increase in microglia burden in db/db and APP/PS1xdb/db mice as previously 
described [14], and this effect was reduced by PP treatment [F(7,3078)=27.34, ##p<0.01 
vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP, 
‡‡p<0.01 vs. Control, Control-PP and PP/PS1-PP] (Figure 5A and 5B). When we 
analyzed the hippocampus, we did not detect significant differences in the proximity 
[F(3,161)=3.90, p=0.1, no further differences detected by Tukey b test] or in SP free areas 
[F(7,585)=1.65, p=0.118] (Figure 5A). 
8. Spontaneous central bleeding is reduced in db/db and APP/PS1xdb/db mice after long-
term PP treatment 
Cortical spontaneous bleeding was increased in the cortex from db/db mice, and this 
effect was more pronounced in APP/PS1xdb/db mice, while PP treatment reversed this 
effect [F(7,218)=2.7, †p=0.011 vs. Control, Control-PP, APP/PS1-PP and db/db-PP] 
(Figure 5C and 5D). This increase in hemorrhage burden was due to an increase in 
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hemorrhage size and number of hemorrhages/mm2 (data not shown). A similar profile 
was observed in the hippocampus although differences did not reach statistical 





AD patients are in a tremendous need of new alternatives to treat or slow down the 
dementia process. The close relationship with T2D [26-27] opens the door to explore 
therapeutic options, including strict metabolic control, that could ultimately prevent or 
delay central nervous system complications. Since T2D is a multifactor disease its 
treatment is usually approached in different ways and PP (metformin, aspirin, a generic 
statin and an ACEi in its composition) has been proposed as a relevant opportunity to 
reduce T2D and its associated complications [13]. Previous epidemiological studies 
have reported the beneficial effects, at central level, of isolated PP components [28-31]. 
However, since we have not performed pharmacological studies we can hardly point 
towards an additive or synergistic effect. To our knowledge, no previous studies have 
addressed the potential beneficial effects of the antidiabetic PP at central level. We have 
tested this approach after long-term treatment of our mixed T2D-AD model, the 
APP/PS1xdb/db mouse. This animal model, resulting from crossing classical models of 
AD (APPswe/PS1dE9 mouse) and T2D (db/db mouse) has been previously 
characterized in our laboratory [14-15]. Since leptin has been widely implicated in cognition 
[32] and long-term potentiation [33], as well as in AD [34-35] we cannot exclude that our 
observations might be, at least partially, due to the lack of the leptin receptor in our animals. 
However, db/db mice have been largely used as a reference model to study type 2 diabetes for 
the last 4 decades. It resembles not only hyperglycaemia, but also, associated comorbidities 
observed in the disease such, as obesity or dyslipidemia, providing a more complete version of 
the illness. While plasma levels of individual components of PP were not determined, 
and this aspect should be carefully taken into consideration, previous studies in mice 
have reported aspirin [36] and simvastatin [37] blood levels after oral administration. 
Also, both central and peripheral effects of individual components of PP have been 
shown in different mouse models after similar interventions [16, 38-40] 
Metabolic assessment revealed that glucose levels were reduced after PP-treatment, as 
expected. These results are consistent with the maintenance of insulin levels in diabetic 
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mice after the treatment, and support the role of PP in β-pancreatic preservation [41]. 
Lipid profile was improved and ACE activity was slightly reduced after PP treatment. 
Previous studies have also reported the beneficial effects of statin treatments [42-43] or 
ACE inhibition [44] on AD and T2D related complications. Therefore, we can not point 
towards a single mechanism that justifies improvement observed after PP treatment. On 
the other hand, this is precisely the objective of this study, since the combination of the 
PP components are regularly used by T2D patients.  
We observed that brain atrophy in db/db and APP/PS1xdb/db mice was not detected in 
PP treated groups. Previous studies from our lab have shown that proliferation and 
neurogenesis are not affected in db/db mice at 4 weeks of age [45]. Moreover, recent 
studies on APP/PS1xdb/db mice, from 4 to 36 weeks of age [14-15], show that brain 
atrophy and cortical thinning seem to be preserved at early stages of the disease. 
Therefore, even though we cannot exclude that deeper assessment could reveal early 
maturation abnormalities, it seems that detected brain atrophy in APP/PS1xd/db mice 
are not due to abnormal development, but to a later degeneration.  
Severe cognitive deterioration has been reported when T2D coexists with dementia [14-
15, 46]. Since leptin has been widely implicated in cognition [32] and long-term 
potentiation [33], as well as in AD [34-35] we cannot exclude that our, at least partially, 
could be due to altered leptin signaling. We observed cognitive impairment in 
APP/PS1xdb/db mice, which was ameliorated by PP treatment. Our data are in 
accordance with previous studies on isolated PP components. While the role of 
metformin remains controversial [28, 47], it has been reported that brain penetrating 
ACEis improve cognitive impairment in AD transgenic mice [19] and in patients with 
cerebrovascular disease [40] or T2D [31]. Moreover, ACE serum activity has been 
correlated with AD severity [48], supporting ACEi as an interesting therapeutic 
alternative at this level. Aspirin effects on cognition are arguable [49], however low-
dose aspirin is readily available and effective in reduction of vascular and platelet 
aggregation [50]. Therefore, even a slight beneficial effect on risk or progression of AD 
might justify this treatment [51]. 
As previously described, APP/PS1xdb/db mice present fewer SP and increased soluble, 
more toxic, Aβ species [14-15] while PP treatment significantly reduced this effect. 
Interestingly, PP treatment also reduced SP burden in APP/PS1 mice, supporting its role 
in amyloid pathology even in the absence of metabolic disorders. Our data suggest that 
PP may interfere with Aβ regular deposition at different levels, depending on the 
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metabolic status, and these observations are in concordance with previous studies with 
isolated PP components. NSAIDs may reduce soluble Aβ42 levels and plaque burden in 
AD mice [52-53]. It has also been shown that statins can reduce Aβ levels and amyloid 
precursor protein C-terminal fragment [54]. Also, simvastatin can induce Aβ 
degradation, by increasing neprilisin secretion [55]. While the role of metformin in 
amyloid pathology remains doubtful [56-57], it may reduce BACE1 expression and 
activity in cell and animal models [58]. Furthermore, metformin can reduce Aβ42 levels 
in diabetic mice [16] and AD related pathology [58], supporting the combined effects of 
all PP components. 
Increased tau phosphorylation has been observed in T2D and mixed AD-T2D animal 
models [15, 22] and PP treatment significantly reduced tau hyperphosphorylation. Our 
results are in agreement with previous studies on tau phosphorylation after individually 
administering PP components. Metformin may induce tau pro-aggregation [59], 
however it also shows a positive effect on tau pathology inducing tau dephosphorylation 
via AMPK/mTOR and PP2A [60]. Likewise, simvastatin may improve tau pathology 
through decreasing neurofibrillary tangles, probably by reducing microglia burden [61]. 
Central inflammation is also a common feature in AD and T2D. In this sense, the anti-
inflammatory effects of metformin [62], simvastatin [63] and perindopril [64] at central 
level have been recently described. In our hands, PP treatment ameliorated microglia 
burden. While microglia activation does not seem to be affected to the same extent in 
the hippocampus, previous studies have also reported that the hippocampus is not 
affected to the same extend in APP/PS1, db/db and APP/PS1xdb/db mice [14-15], 
making differences among groups harder to detect. It has been reported that reduced 
microglia activation might be derived from its effects on tau and amyloid pathology. 
However, it is also feasible that PP treatment may specifically reduce central 
inflammation. On the other hand we can not exclude that the reduction in the 
NeuN/DAPI ratio, observed in db/db and APP/PS1xdb/db mice, might also reflect an 
increased inflammatory process, that is partially restored after PP treatment, ultimately 
accounting for the limited effect of PP treatment of synaptic densities in the areas close 
to SP.  
Both T2D and AD have been closely related to vascular dysfunction, and preceding 
studies have reported increased spontaneous bleeding in db/db mice [22]. Also, a 
synergistic vascular damage is observed when AD and T2D are set together [3, 14-15]. 
While we have not analyzed other brain regions or addressed white matter disease in our 
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mice, previous studies have pointed out that diabetic mice have significantly increased 
white matter damage after induced stroke [65]. We observed a reduction of cortical 
microhemorrhages in our mixed model after long-term PP treatment, in line with 
previous studies on individual PP components: aspirin [50], simvastatin [63], 
perindopril [66] and metformin [38], supporting a role for PP cocktail to ameliorate 
vascular pathology.  
Altogether, PP might be an appealing approach that combines inexpensive, safe and 
approved components (metformin+aspirin+statin+perindopril). PP interferes with tau 
and amyloid pathology, inflammation, and spontaneous bleeding, and improves 
cognitive impairment. Our data provide the basis to further analyze the role of PP, as an 
alternative or adjuvant, to slow down or delay the central pathology associated with 
T2D and AD. 
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Figure legends  
Figure 1. PP-treatment improves plasma parameters in db/db and APP/PS1xdb/db 
mice and rescues cognitive impairment. A) Body weight was significantly higher in 
diabetic mice (db/db and APP/PS1xdb/db) when compared with Control and APP/PS1 
groups, and PP treatment also contributed to body weight gain (weeks 4, 8, 12: ‡‡p<0.01 
vs. Control, Control-PP, APP/PS1 and APP/PS1-PP; weeks 16, 20 and 24: ††p<0.01 vs. 
Control, Control-PP, APP/PS1, APP/PS1-PP, db/db and APP/PS1xdb/db, ‡‡ p<0.01 vs. 
Control, Control-PP, APP/PS1 and APP/PS1-PP). B) Blood glucose levels were reduced 
after PP treatment in diabetic mice and this effect was significantly increased in 
APP/PS1xdb/db mice after 12 weeks of treatment (week 4: p=0.07; weeks 8 and 12: 
††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and 
APP/PS1xdb/db-PP, ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP; 
weeks 16, 20 and 24: **p<0.01 vs. rest of the groups, ††p<0.01 vs. Control, Control-PP, 
APP/PS1, APP/PS1-PP, db/db-PP and APP/PS1xdb/db-PP, ‡‡p<0.01 vs. Control, 
Control-PP, APP/PS1 and APP/PS1-PP). C) Insulin levels were significantly increased in 
diabetic mice (db/db and APP/PS1xdb/db) before the commencement of the treatment, at 
4 weeks of age, when compared with Control and APP/PS1 mice. Insulin exhaustion was 
more pronounced in APP/PS1xdb/db mice than in db/db mice and PP treatment rescued 
insulin levels in diabetic mice (week 4: ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and 
APP/PS1-PP; weeks 8, 12 and 16: ‡‡p<0.01 vs. Control, Control-PP, APP/PS1, 
APP/PS1-PP, db/db and APP/PS1xdb/db, ††p<0.01 vs. Control, Control-PP, APP/PS1, 
APP/PS1-PP; weeks 20 and 24: ‡‡p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-
PP, db/db and APP/PS1xdb/db. D) Episodic memory was significantly improved after PP 
treatment, as observed in the NOD test. A significant improvement was observed in 
"what" and "where” paradigms for APP/PS1, db/db and APP/PS1xdb/db mice after PP, 
when compared with untreated mice: “what” (††p<0.01 vs. Control, Control-PP, db/db-
PP and APP/PS1xdb/db-PP, ##p<0.01 vs. Control and Control-PP, ‡‡p<0.01 vs. Control), 
“where” (‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP, ##p<0.01 vs. 
Control and Control-PP). While a similar profile was observed for “when” paradigm, 
differences did not reach statistical significance (p=0.101). E) Spatial learning 
impairment in the MWM test was partially reverted after PP treatment in APP/PS1 mice. 
db/db and APP/PS1xdb/db mice on PP also presented significantly shorter times to find 
the hidden platform along the acquisition phase, when compared with untreated 
littermates. (day 1: ##p<0.01 vs. Control and Control-PP; day 2: ##p<0.01 vs. Control 
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and Control-PP, ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP, ††p<0.01 
vs. Control, Control-PP, APP/PS1, APP/PS1-PP and db/db-PP; day 3: ##p<0.01 vs. 
Control and Control-PP, ‡‡p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP, 
††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and 
APP/PS1xdb/db-PP; day 4: ♯♯p<0.01 vs. Control, Control-PP and APP/PS1, ‡‡p<0.01 vs. 
Control, Control-PP, APP/PS1 and APP/PS1-PP, **p<0.01 vs. rest of the groups). F) In 
the retention phase of the MWM, when the platform was removed from the pool, we also 
observed that memory impairment in db/db and APP/PS1xdb/db mice was completely 
recovered after PP administration (††p=0.003 vs. Control, Control-PP, APP/PS1, 
APP/PS1-PP, db/db-PP and APP/PS1xdbdb-PP). 
 
Figure 2. PP treatment improves central atrophy in db/db mice. A) Brain weight was 
significantly reduced in db/db and APP/PS1xdb/db mice when compared to Control and 
APP/PS1 mice. Long-term PP treatment significantly reduced brain weight loss, although 
PP-treated groups did not reach Control values (**p<0.01 vs. rest of the groups, ‡‡p<0.01 
vs. Control, control-PP, APP/PS1, APP/PS1-PP and db/db-PP, ††p<0.01. vs. Control, 
control-PP, APP/PS1 and APP/PS1-PP). B) Similarly, cortical size compromise in db/db 
mice was improved after PP treatment and this effect reached statistical significance in 
APP/PS1xdb/db mice (**p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-
PP and APP/PS1xdb/db-PP, ††p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP). 
C) When we measured hippocampus size, differences did not reach statistical significance 
among groups (p=0.997). D) Illustrative example of cresyl violet staining where cortical 
thinning, observed in db/db and APP/PS1xdb/db mice, improves after PP treatment. 
Scale bar=250 µm. E) Immunostaining for NeuN-possitive cells was reduced in SP-free 
areas, both in db/db and APP/PS1xdb/db mice. PP treatment significantly improved this 
situation and the number of NeuN-possitive cells was increased both in db/db-PP and 
APP/PS1xdb/db mice (‡‡p<0.01 vs.Control, Control-PP, db/db-PP and APP/PS1xdb/db-
PP, ##p<0.01 vs. Control). Also, in the proximity of SP, reduced NeuN+/DAPI ratio in 
APP/PS1 and APP/PS1xdb/db mice improved after PP when compared to untreated 
animals (‡‡p=0.08 vs. APP/PS1xdb/db-PP). F) Illustrative example of NeuN (red) 
immunostaining and DAPI (blue) counterstain. PP treatment restores NeuN+/DAPI 
ratios in APP/PS1, db/db and APP/PS1xdb/db mice. Scale bar: 50 µm.  
 
 28 
Figure 3. PP-treatment preserves synaptic density in db/db and APP/PS1xdb/db 
treated mice. A) No differences were detected among groups when PSD95 densities 
were analyzed by array tomography in the proximity of the SP (p=0.127). In SP free 
areas, PSD95 densities were lower in db/db mice and this effects worsened in 
APP/PS1xdb/db mice. Long-term PP treatment significantly increased PS95 densities in 
db/db-PP and APP/PS1xdb/db-PP groups, that reached control values (**p<0.01 vs. rest 
of the groups, ‡‡p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP and 
APP/PS1xdb/db-PP). B) Similarly, synaptophysin densities, analyzed by array 
tomography, were not significantly different among groups in the proximity of the SP, 
(p=0.474). However, in SP free areas, synaptophysin densities were significantly lower in 
db/db and APP/PS1xdb/db mice. PP treatment significantly improved synaptophysin 
densities in db/db and APP/PS1xdb/db treated mice (††p<0.01 vs. Control, Control-PP, 
APP/PS1, APP/PS1-PP, ‡‡p<0.01 vs. Control and Control-PP, ##p<0.01 vs. Control-PP). 
C) Illustrative example of SP (anti-AW7 in grey) and synaptic proteins PSD95 (green), 
synapthophysin (red) and nuclear stain with DAPI (blue). Scale bar=10 µm. 
 
Figure 4. PP treatment ameliorates amyloid pathology and reduces tau 
hyperphosphorylation. A) SP burden was significantly lower in APP/PS1xdb/db mice 
when compared with APP/PS1 animals. PP treatment reduced amyloid SP burden in 
APP/PS1 mice after 4G8 immunostainning and thioflavin S staining (TS) (**p<0.01 vs. 
rest of the groups, ††p<0.01 vs. APP/PS1xdb/db and APP/PS1xdb/db-PP). A similar 
profile was observed in the hippocampus after 4G8 immunostaining (††p<0.01 vs. 
APP/PS1xdb/db and APP/PS1xdb/db-PP]) and TS staining (‡‡p=0.026 vs. 
APP/PS1xdb/db). B) Illustrative example of SP deposition after 4G8 immunostaining 
(red). Scale bar=250 μm. C) Cortical soluble Aβ40 levels were slightly increased in 
APP/PS1xdb/db mice when compared with APP/PS1 animals and PP reduced this effect 
(‡p<0.035 vs. APP/PS1xdb/db-PP). Soluble Aβ42 levels showed similar profile 
although differences did not reach statistical significance (p=0.075). When we analyzed 
insoluble Aβ levels, we observed a similar profile to that detected for SP burden: 
insoluble Aβ40 levels were significantly higher in APP/PS1 mice when compared with 
APP/PS1xdb/db mice, however PP treatment reduced insoluble Aβ40 in the APP/PS1 
group (*p=0.019 vs. rest of the groups). A similar profile was observed for Aβ42 levels 
although differences did not reach statistical significance (p=0.081). Hippocampus 
presented a similar profile with higher soluble Aβ levels in APP/PS1xdb/db mice that 
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were reduced after PP treatment, however differences did not reach statistical 
significance (Aβ40, p=0.144; Aβ42, p=0.130). Insoluble Aβ40 levels were higher in 
APP/PS1 mice and this effect was counterbalanced after PP treatment (**p=0.005 vs. 
rest of the groups). Insoluble Aβ42 were also slightly increased in APP/PS1 mice and 
reduced after PP treatment, although differences did not reach statistical significance 
(p=0.083). D) Tau phosphorylation, analyzed by western-blot, showed that increased 
hyperphosphorylation in the cortex from db/db and APP/PS1xdb/db mice was 
significantly reduced after PP treatment in both groups (†p=0.02 vs. Control, Control-
PP, APP/PS1 and APP/PS1-PP). A similar profile was observed in the hippocampus 
where PP significantly reduced tau phosphorylation in db/db and APP/PS1xdb/db mice 
(##p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and 
APP/PS1xdbd/db-PP, ††p<0.01 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP). 
G) Illustrative example of cortical tau phosphorylation in all groups under study.  
 
Figure 5. PP treatment reduces central inflammation and spontaneous bleeding. A) 
Microglia burden, measured after IBA-1 immunohistochemistry, was increased in the 
proximity of cortical SP in APP/PS1 mice, when compared with APP/PS1xdb/db mice. 
Long-term PP treatment significantly reduced microglia burden, both in APP/PS1 and 
APP/PS1xdb/db mice (**p<0.05 vs. rest of the groups, ††p<0.01 vs. APP/PS1 and 
APP/PS1-PP, ‡‡p<0.01 vs. APP/PS1). In areas far from SP, increased microglia burden 
in db/db and APP/PS1xdb/db mice was also counterbalanced by PP treatment 
(##p<0.01 vs. Control, Control-PP, APP/PS1, APP/PS1-PP, db/db-PP and 
APP/PS1xdb/db-PP, ‡‡p<0.01 vs. Control, Control-PP and APP/PS1-PP). Hippocampal 
microglia burden showed a similar trend, however differences among groups were not 
statistically significant close (p=0.1) or far from SP (p=0.118). B) Representative image 
of SP (anti-4G8 immunostaining, red) and microglia inmunostaining (anti-IBA1 
immunostaining, green) in the cortex. Scale bar=25 μm. C) Hemorrhage burden, 
analyzed by Prussian blue staining, was also significantly increased in the cortex from 
APP/PS1xdb/db mice, while PP treatment reduced spontaneous bleeding in 
APP/PS1xdb/db-PP mice, that reached control values (*p=0.011 vs. Control, Control-
PP, APP/PS1-PP and db/db-PP). A similar profile was detected in the hippocampus 
although differences did not reach statistical significance (p=0.637). D) Illustrative 
example of cortical hemorrhages stained with Prussian blue. Green arrows point at 
individual hemorrhages. Scale bar=200 μm.  
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Control   78.91±4.72 40.55±8.58 23.64±2.00 52.36±  2.53 125.19±11.01 
Control-PP   84.56±4.72 36.31±6.76 24.13±2.05 52.07±  2.33 117.31±15.68 
APP/PS1   76.55±4.79 32.45±6.50 25.00±2.50 56.18±  3.43 133.61±10.62 
APP/PS1-PP   82.75±3.68 33.67±6.67 20.83±1.13 57.00±  3.59 114.74±16.39 
db/db 133.13±16.87†† 16.22±6.08     40.78±6.91†† 85.00±17.50   93.37±17.50 
db/db-PP 116.43±14.33 21.14±8.50 28.29±3.41 70.29±  7.32   70.29±17.94 
APP/PS1xdb/db 111.50±14.33   9.71±5.40 38.50±9.03   101.00±19.78†† 149.32±14.42 
APP/PS1xdb/db-PP   89.43±16.83 25.86±8.71     31.57±3.21## 72.00±  6.24     56.65±16.55† 
 
Total cholesterol levels were increased in db/db mice and PP treatment counterbalanced this effect (††p=0.002 vs. Control, Control-PP, APP/PS1 
and APP/PS1-PP). HDL levels were reduced in db/db and APP/PS1xdb/db mice and PP treatment improved this effect, although differences did 
not reach statistical significance (p=0.084). Increased LDL levels in db/db and APP/PS1xdb/db mice were reduced after PP treatment (††p=0.002 
vs. Control, Control-PP, APP/PS1 and APP/PS1-PP and ##p=0.002 vs. APP/PS1-PP). Increased triglycerides levels in APP/PS1xdb/db mice 
were reduced after PP treatment (††p=0.001 vs. Control, Control-PP, APP/PS1 and APP/PS1-PP). ACE activity was reduced in db/db mice after 
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